-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background statins can regulate inflammation in addition to having effective fat-lowering effects.
, data on statin use and the risk of inflammatory bowel disease (IBD) are not consistent.
, the study aims to explore the link between statin use and inflammatory bowel disease.
method researchers searched a national database of inpatients and outpatients in Sweden and included adults diagnosed with Crohn's disease (CD, n s 7,637) or ulcerative colitis (UC, n s 15,652) in the study.
each case was matched to 10 general population controls (n s 232,890).
to extract data on statin prescriptions from the prescription drug registry.
estimated the ratio of IBD risk (OR) using the Logistic regression model based on statin exposure.
results in a multivariable adjustment model, there was a lower risk of CD (OR s 0.71; 95% CI, 0.63-0.79) compared to not using statins, while UC did not have such a relationship (OR s 1.03; 95% CI, 0.96-1.11).
the lowest CD OR currently used in statins (OR s 0.67; 95% CI, 0.60-0.75).
For CD, the risk of onset is associated with the cumulative dose of statins: maximum intake (OR 0.66; 95% CI, 0.55-0.80), and for UC, statin intake is not associated with the risk of disease.
concluded that statin use was associated with a lower CD risk, but not UC.
for current statins, the correlation with CD risk appears to be strongest.
suggests that statin use may affect the development of CD.